Neoplasm
RecruitingStudy of Zenocutuzumab for Patients with Solid Tumors with NRG1 Fusion
- Disease:Neoplasm
- Substances:Zenocutuzumab
Austria- Participants:18–64 years · 65+ years
- Substances:Zenocutuzumab
- Sponsor:Partner Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
19 Muzzey Street, 02421-5256, United States
Partner Therapeutics Inc. is active in clinical research focused on solid tumors, with attention to tumors driven by actionable molecular alterations and treatment-resistant disease.
Its research activity reflects interest in identifying therapeutic options for patients whose tumors are defined by specific genetic features, including NRG1 fusions.
Partner Therapeutics Inc. runs clinical trials in conditions such as Neoplasm, among others.
Clinical trials run by this sponsor – those enrolling participants first.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.